{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-22-000036","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2022-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.977903+00:00","generated_at":"2026-06-24T15:17:34.620331+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO","bullets":["Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.","Americas rev grew 8% YoY to $70.9M; EMEA fell 11% to $25.6M; APAC fell 15% to $18.1M.","CEO says results 'fell short of our expectations'; full Q2 results and FY2022 guidance on Aug 8.","Appointed Jim Wilbur, Ph.D., as Chief Commercial Officer effective July 27; outgoing CCO Brad Crutchfield to transition through Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-22-000036","json":"https://secwatch.observer/filing/0001770787-22-000036.json","markdown":"https://secwatch.observer/filing/0001770787-22-000036.md","text":"https://secwatch.observer/filing/0001770787-22-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/0001770787-22-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/txg-20220712.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T15:17:34.620331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}